Hydroxyzine Dosing, Contraindications, and Monitoring in Adults
For adults with urticaria or allergic conditions, hydroxyzine should be dosed at 10-50 mg at night, with the dose halved in moderate renal impairment and avoided entirely in severe hepatic or renal disease, prolonged QT interval, early pregnancy, and in patients taking QT-prolonging medications. 1
Dosing Recommendations
Standard Adult Dosing
- Urticaria/Allergic Conditions: 10-50 mg at bedtime 2
- Generalized Anxiety Disorder: 50 mg/day (typically divided or given at night) 3, 4
- Insomnia: 25-100 mg at bedtime 5
Dosing Strategy
Evening/bedtime dosing is strongly preferred because it mitigates the significant psychomotor impairment and drowsiness seen with divided doses while maintaining full antihistaminic efficacy the following morning 6. This approach reduces reaction time degradation compared to divided dosing schedules.
Dose Adjustments
Renal Impairment:
- Moderate impairment (CrCl 10-20 mL/min): Reduce dose by 50% 2
- Severe impairment (CrCl <10 mL/min): Avoid completely 2
Hepatic Impairment:
- Severe liver disease: Avoid completely due to inappropriate sedating effects and risk of precipitating hepatic coma 2
Absolute Contraindications
The FDA label and guidelines establish clear contraindications 1:
- Prolonged QT interval (hydroxyzine causes dose-dependent QT prolongation and risk of Torsade de Pointes) 1, 7
- Early pregnancy (specifically contraindicated in first trimester due to fetal abnormalities in animal studies) 2, 1
- Known hypersensitivity to hydroxyzine, cetirizine, or levocetirizine 1
- Severe renal impairment (CrCl <10 mL/min) 2
- Severe hepatic disease 2
Critical Drug Interactions
Avoid concurrent use with:
- Drugs that prolong QT interval (tricyclic antidepressants, macrolide antibiotics, imidazole antifungals) 2, 7
- Multiple cardiovascular medications in patients with underlying cardiac disease 7
The combination of cardiovascular disorders plus concomitant QT-prolonging drugs represents the greatest risk factor for arrhythmias 7.
Monitoring Considerations
Baseline Assessment
- ECG screening for QT interval in all patients, particularly those with:
- Cardiovascular disease
- Electrolyte abnormalities
- Concomitant medications affecting cardiac conduction 7
- Renal function (creatinine clearance)
- Hepatic function tests
- Pregnancy status in women of childbearing age 2, 1
Ongoing Monitoring
- ECG monitoring is recommended if overdose occurs or if cardiac symptoms develop 1
- Monitor for excessive sedation, especially during the first week (drowsiness occurs in ~28% initially but typically resolves) 4
- Assess for anticholinergic effects: dry mouth (14%), urinary retention, constipation 8, 4
Common Pitfalls and Caveats
Sedation Management: While drowsiness is common initially (28% in first week), it progressively diminishes with continued use 4. This transient nature should be communicated to patients to improve adherence.
Pregnancy Considerations: Despite chlorphenamine being traditionally preferred in the UK due to its safety record, hydroxyzine is the only antihistamine specifically contraindicated in early pregnancy per its product labeling 2. This is a critical distinction.
Overdose Recognition: Hypersedation is the most common manifestation, but QT prolongation and Torsade de Pointes are the most dangerous complications requiring ECG monitoring 1. There is no specific antidote; management is supportive with IV fluids and vasopressors (levarterenol or metaraminol—never epinephrine as hydroxyzine counteracts its pressor action) 1.
Efficacy Considerations: When used for urticaria at higher doses (above manufacturer recommendations), hydroxyzine demonstrates antiallergic effects on mast cell mediator release 2. The practice of dose escalation is common when benefits outweigh risks, though this represents off-label use.
Rebound/Withdrawal: Studies show no rebound anxiety or withdrawal symptoms after abrupt discontinuation, even after 4 weeks of continuous use 4, which distinguishes it favorably from benzodiazepines.